Entry Detail


General Information

Database ID:exR0093481
RNA Name:hsa-miR-3171
RNA Type:miRNA
Chromosome:chr14
Starnd:-
Coordinate:
Start Site(bp):27633246End Site(bp):27633269
External Links:hsa-miR-3171



Disease Information

Disease Name:Benign Ovarian Disease
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D010049
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Ovarian Diseases//Disease, Ovarian//Diseases, Ovarian//Ovarian Disease



Expression Detail

GEO ID:GSE106817
Description:Integrated extracellular microRNA profiling for ovarian cancer screening
Experimental Design:Cancer vs Control
Case Disease Type:Benign Ovarian Disease
Case Disease SubType:NA
Case Sample:Benign Ovarian Disease
Control Sample:Non-Cancer
Number of Case:29
Number of Control:2759
Number of Samples:2788





Regulatory Relationship

mRNA targets:NA
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001265
chr3
9711115
9712854
+
hsa_circ_0000798
chr17
65941524
65944422
+
hsa_circ_0001865
chr9
86292641
86293514
-
hsa_circ_0000799
chr17
65941524
65972074
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC016876.2
chr17
7581964
7584086
-
AC145207.5
chr17
81878425
81881106
-
DLEU2
chr13
49956670
50125720
-
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
OTUD6B-AS1
chr8
91059318
91070583
-
Display:



Experiment Detail

GEO ID:GSE106817
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21263
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2535
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
RNA library preparation protocol:miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.



Reference

PMID:30333487
Title:Integrated extracellular microRNA profiling for ovarian cancer screening
Author:Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T
Journal:Nat Commun. 2018 Oct 17;9(1):4319.
Description:to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.